Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Inactivated Quadrivalent Influenza Vaccine in Children Aged 3-8 Years
NCT05389137Phase 4Unknown
- Sponsor
- Wuhan Institute of Biological Products
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of inactivated quadrivalent influenza virus split vaccine in influenza, sponsored by Wuhan Institute of Biological Products. Status: unknown.
02
Drugs
inactivated quadrivalent influenza virus split vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05389137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389137.